[A24-34] Midostaurin (acute myeloid leukaemia) – Addendum to Project A23-110
Last updated 02.05.2024
Project no.:
A24-34
Commission:
Commission awarded on 27.03.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
In combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia who are FMS-like tyrosine kinase 3 mutation-positive
Unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A24-34_en
| Project no. | Title | Status |
|---|---|---|
| A23-110 | Midostaurin (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-05-02 A G-BA decision was published.